Literature DB >> 23077973

Cardiovascular risk of resistant hypertension: dependence on treatment-time regimen of blood pressure-lowering medications.

Diana E Ayala1, Ramón C Hermida, Artemio Mojón, José R Fernández.   

Abstract

In resistant hypertension, ingesting one or more blood pressure (BP)-lowering medications at bedtime is associated with significant reduction of sleep-time BP, a sensitive prognostic marker of cardiovascular disease (CVD) risk. This randomized trial investigated if bedtime therapy with at least one hypertension medication exerts better BP control and CVD risk reduction than conventional, morning-time therapy with all medications. We conducted a prospective, open-label, blinded-endpoint trial on 776 patients (387 men/389 women) with resistant hypertension, 61.6 ± 11.2 (mean ± SD) yrs of age. Patients were randomized to ingest all their prescribed hypertension medications upon awakening or ≥1 of them at bedtime. BP was measured by ambulatory monitoring for 48 h at baseline, and again annually or more frequently (quarterly) if treatment adjustment was required. After a median follow-up of 5.4 yrs (range, .5-8.5 yrs), participants ingesting ≥1 hypertension medications at bedtime showed a significantly lower hazard ratio (HR) of total CVD events (adjusted by age, sex, and diabetes) than those ingesting all medications upon awakening (.38 [95% CI: .27-.55]; number of events 102 vs. 41; p < .001). The difference between groups in the adjusted HR of major CVD events (a composite of CVD death, myocardial infarction, ischemic stroke, and hemorrhagic stroke) was also statistically significant (.35 [95% CI: .18-.68]; number of events 32 vs. 12; p = .002). At the last evaluation, patients treated with the bedtime versus awakening-time-treatment regimen showed significantly lower sleep-time systolic/diastolic BP mean values (121.6/65.4 vs. 113.0/61.1 mm Hg; p < .001) and higher prevalence of controlled ambulatory BP (61% vs. 46%; p < .001). The progressive decrease in the sleep-time systolic BP mean during follow-up was the most significant predictor of event-free survival (15% risk reduction per 5 mm Hg decreased asleep systolic BP mean). Among patients with resistant hypertension, ingestion of at least one hypertension medication at bedtime, compared with all medications upon waking, resulted in improved ambulatory BP control and fewer hard and soft CVD events.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077973     DOI: 10.3109/07420528.2012.701455

Source DB:  PubMed          Journal:  Chronobiol Int        ISSN: 0742-0528            Impact factor:   2.877


  18 in total

Review 1.  Chronotherapeutics of conventional blood pressure-lowering medications: simple, low-cost means of improving management and treatment outcomes of hypertensive-related disorders.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Juan J Crespo; María T Ríos; Ana Moyá; Francesco Portaluppi
Journal:  Curr Hypertens Rep       Date:  2014-02       Impact factor: 5.369

Review 2.  Chronotherapy for Hypertension.

Authors:  N P Bowles; S S Thosar; M X Herzig; S A Shea
Journal:  Curr Hypertens Rep       Date:  2018-09-28       Impact factor: 5.369

3.  Endothelial function in postmenopausal women with nighttime systolic hypertension.

Authors:  Faye S Routledge; Alan L Hinderliter; Judith McFetridge-Durdle; James A Blumenthal; Nicola J Paine; Andrew Sherwood
Journal:  Menopause       Date:  2015-08       Impact factor: 2.953

Review 4.  Chronotherapy improves blood pressure control and reduces vascular risk in CKD.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; Artemio Mojón; José R Fernández; Juan J Crespo; Ana Moyá; María T Ríos; Francesco Portaluppi
Journal:  Nat Rev Nephrol       Date:  2013-04-23       Impact factor: 28.314

Review 5.  Sleep-time ambulatory blood pressure as a novel therapeutic target for cardiovascular risk reduction.

Authors:  R C Hermida; D E Ayala; A Mojón; M H Smolensky; F Portaluppi; J R Fernández
Journal:  J Hum Hypertens       Date:  2014-02-06       Impact factor: 3.012

6.  Bedtime ingestion of hypertension medications reduces the risk of new-onset type 2 diabetes: a randomised controlled trial.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

7.  Sleep-time BP: prognostic marker of type 2 diabetes and therapeutic target for prevention.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetologia       Date:  2015-09-23       Impact factor: 10.122

Review 8.  Around-the-clock ambulatory blood pressure monitoring is required to properly diagnose resistant hypertension and assess associated vascular risk.

Authors:  Ramón C Hermida; Diana E Ayala; María T Ríos; José R Fernández; Artemio Mojón; Michael H Smolensky
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 9.  Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks.

Authors:  Ramón C Hermida; Diana E Ayala; Michael H Smolensky; José R Fernández; Artemio Mojón; Francesco Portaluppi
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

10.  Ethical complexities in standard of care randomized trials: A case study of morning versus nighttime dosing of blood pressure drugs.

Authors:  Scott Y H Kim; Franklin G Miller
Journal:  Clin Trials       Date:  2015-09-22       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.